Home Colorectal Cancer VolitionRx Fine-Tunes Nucleosome Tech to Advance Cancer Dx Pipeline; Eyes COVID-19 Testing

VolitionRx Fine-Tunes Nucleosome Tech to Advance Cancer Dx Pipeline; Eyes COVID-19 Testing

36
0

NEW YORK – After several years of refining and optimizing its assay platform, epigenetic diagnostic firm VolitionRx is nearing its first implementation in cancer detection, while also eyeing a detour in infectious disease spurred by the emerging coronavirus pandemic.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

https://www.360dx.com/molecular-diagnostics/volitionrx-fine-tunes-nucleosome-tech-advance-cancer-dx-pipeline-eyes-covid-19

Advertisements

This site uses Akismet to reduce spam. Learn how your comment data is processed.